Aurobindo Pharma Reaches 52-Week High: Should Investors Buy or Take Profits?
Stock Radar: Aurobindo Pharma stock hits fresh 52-week high in April; time to buy or book profits?
The Economic Times
Image: The Economic Times
Aurobindo Pharma Ltd has reached a new 52-week high in April, with analysts suggesting a potential target of ₹1,496 in the coming weeks. The stock has shown strong support from its 20-week moving average, indicating a continued upward trend.
- 01Aurobindo Pharma hit a new 52-week high in April.
- 02Analysts suggest a target price of ₹1,496 in the next 3-4 weeks.
- 03The stock has strong support from its 20-week moving average.
- 04A buy signal was triggered by the Supertrend indicator in March 2026.
- 05Short-term traders may benefit from current market conditions.
Advertisement
In-Article Ad
Aurobindo Pharma Ltd, a key player in the pharmaceutical industry, has achieved a fresh 52-week high in April, indicating a robust performance. Analysts recommend that short-term traders consider buying the stock, with a target price set at ₹1,496 over the next 3-4 weeks. The stock's upward momentum is supported by its 20-week moving average, which has acted as a strong support level since September 2025. Additionally, a buy signal was generated by the Supertrend indicator back in March 2026, further suggesting that the rally may continue. Investors are weighing the decision to either capitalize on profits or hold for potential further gains.
Advertisement
In-Article Ad
Investors in Aurobindo Pharma may see short-term gains if the stock continues to rise, potentially impacting their investment strategies.
Advertisement
In-Article Ad
Reader Poll
Are you considering investing in Aurobindo Pharma stock?
Connecting to poll...
Read the original article
Visit the source for the complete story.